Funds › Ally Bridge Group (NY) LLC
Ally Bridge Group (NY) LLC
13F for Q2 2026, filed Aug 14, 2026. 23 positions worth $113.1M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Ally Bridge Group (NY) LLC in the latest 13F quarter?
Using 13F.ai, how has Ally Bridge Group (NY) LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Ally Bridge Group (NY) LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | NERV Minerva Neurosciences, Inc | 2.18M | $12.1M | 10.7% | +31.4% | 13F ↗ |
| 2 | PMN ProMIS Neurosciences Inc. | 620,319 | $8.2M | 7.2% | +49.8% | 13F ↗ |
| 3 | TRAX First Tracks Biotherapeutics, Inc. · Ord Shs *A* | 284,287 | $5.7M | 5.1% | New | 13F ↗ |
| 4 | AXSM Axsome Therapeutics, Inc. | 16,493 | $4.0M | 3.6% | New | 13F ↗ |
| 5 | ASMB Assembly Biosciences, Inc. | 140,000 | $3.8M | 3.4% | New | 13F ↗ |
| 6 | WHWK Whitehawk Therapeutics, Inc. | 817,939 | $3.7M | 3.3% | Unchanged | 13F ↗ |
| 7 | EWTX Edgewise Therapeutics, Inc. | 83,300 | $3.4M | 3.0% | -48.3% | 13F ↗ |
| 8 | CLYM Climb Bio, Inc. | 249,172 | $3.2M | 2.9% | New | 13F ↗ |
| 9 | KURA Kura Oncology, Inc. | 290,000 | $3.2M | 2.8% | New | 13F ↗ |
| 10 | CTMX CytomX Therapeutics, Inc. | 775,000 | $2.9M | 2.6% | -13.9% | 13F ↗ |
| 11 | AVTX Avalo Therapeutics, Inc. | 150,000 | $2.8M | 2.5% | New | 13F ↗ |
| 12 | PALI Palisade Bio, Inc. | 1.23M | $2.6M | 2.3% | New | 13F ↗ |
| 13 | SLDB Solid Biosciences Inc. | 255,959 | $2.6M | 2.3% | -66.6% | 13F ↗ |
| 14 | ANTX AN2 Therapeutics, Inc. | 526,315 | $2.5M | 2.3% | Unchanged | 13F ↗ |
| 15 | URGN UroGen Pharma Ltd. | 69,183 | $2.5M | 2.3% | -65.8% | 13F ↗ |
| 16 | CATX Perspective Therapeutics, Inc. | 743,958 | $2.5M | 2.2% | -19.7% | 13F ↗ |
| 17 | IDYA IDEAYA Biosciences, Inc. | 67,500 | $2.5M | 2.2% | New | 13F ↗ |
| 18 | IVA Inventiva S.A. · ADR | 634,800 | $2.4M | 2.1% | -14.8% | 13F ↗ |
| 19 | ALMS Alumis Inc. | 76,459 | $2.2M | 1.9% | -54.2% | 13F ↗ |
| 20 | OVID Ovid Therapeutics Inc. | 624,561 | $1.7M | 1.5% | -77.8% | 13F ↗ |
| 21 | EPRX Eupraxia Pharmaceuticals Inc. · Com 298736 Al 3 Euronet Worldwide Inc Note 0.750% 3/1 | 252,175 | $1.7M | 1.5% | -61.8% | 13F ↗ |
| 22 | IBIO iBio, Inc. | 390,147 | $682.8K | 0.6% | New | 13F ↗ |
| 23 | TRAW Traws Pharma, Inc. | 786,236 | $663.0K | 0.6% | New | 13F ↗ |
Changes since Q1 2026
10 new, 2 added to, 9 trimmed, 8 exited, 2 unchanged. By estimated dollars.
New positions (10)
| TRAX First Tracks Biotherapeutics, Inc. · Ord Shs *A* | 284,287 | New | $5.7M |
| AXSM Axsome Therapeutics, Inc. | 16,493 | New | $4.0M |
| ASMB Assembly Biosciences, Inc. | 140,000 | New | $3.8M |
| CLYM Climb Bio, Inc. | 249,172 | New | $3.2M |
| KURA Kura Oncology, Inc. | 290,000 | New | $3.2M |
| AVTX Avalo Therapeutics, Inc. | 150,000 | New | $2.8M |
| PALI Palisade Bio, Inc. | 1.23M | New | $2.6M |
| IDYA IDEAYA Biosciences, Inc. | 67,500 | New | $2.5M |
| IBIO iBio, Inc. | 390,147 | New | $682.8K |
| TRAW Traws Pharma, Inc. | 786,236 | New | $663.0K |
Added to (2)
Trimmed (9)
| OVID Ovid Therapeutics Inc. | 624,561 | -77.8% | -$5.9M |
| SLDB Solid Biosciences Inc. | 255,959 | -66.6% | -$5.1M |
| URGN UroGen Pharma Ltd. | 69,183 | -65.8% | -$4.9M |
| EWTX Edgewise Therapeutics, Inc. | 83,300 | -48.3% | -$3.2M |
| EPRX Eupraxia Pharmaceuticals Inc. · Com 298736 Al 3 Euronet Worldwide Inc Note 0.750% 3/1 | 252,175 | -61.8% | -$2.7M |
| ALMS Alumis Inc. | 76,459 | -54.2% | -$2.5M |
| CATX Perspective Therapeutics, Inc. | 743,958 | -19.7% | -$622.7K |
| CTMX CytomX Therapeutics, Inc. | 775,000 | -13.9% | -$468.8K |
| IVA Inventiva S.A. · ADR | 634,800 | -14.8% | -$417.7K |
Exited (8)
| PRAX Praxis Precision Medicines, Inc. | 32,810 | Exited | -$10.6M |
| Soleno Therapeutics Inc | 200,000 | Exited | -$6.7M |
| CMPS COMPASS Pathways Plc · ADR | 1.04M | Exited | -$5.8M |
| TARS Tarsus Pharmaceuticals, Inc. | 80,859 | Exited | -$5.7M |
| ABVX Abivax SA · ADR | 33,712 | Exited | -$3.8M |
| CAPR Capricor Therapeutics, Inc. | 113,899 | Exited | -$3.5M |
| IKT Inhibikase Therapeutics, Inc. | 1.32M | Exited | -$2.2M |
| RLMD Relmada Therapeutics, Inc. | 210,525 | Exited | -$1.5M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer